Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pingli Wang

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 31, 2024
Ficonalkib (SY-3505) in Advanced ALK-Positive NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 1/2 StudyYuankai Shi, Xingsheng Hu, Xingya Li, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 10, 2025
Targeting Cystine Metabolism in the Lung Cancer Environment Enhances the Efficacy of Immune Checkpoint InhibitionYun Xu, Shumin Li, Jiaji Wu, et al.
The Lancet. Respiratory Medicine|June 13, 2024
Garsorasib in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trialZiming Li, Xiaomin Dang, Dingzhi Huang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 22, 2023
D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS<sup>G12C</sup> in Patients With NSCLC: Phase 1 Study ResultsZiming Li, Zhengbo Song, Yanqiu Zhao, et al.
Future Oncology (London, England)|June 3, 2026
Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 studyZhiwei Chen, Fang Yang, Zhou Jiang, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2025
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 studyZhengbo Song, Ziming Li, Yiping Zhang, et al.
Lancet (London, England)|May 31, 2026
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in ChinaShun Lu, Baogang Liu, Yongzhong Luo, et al.
Lancet (London, England)|October 22, 2025
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trialZhiwei Chen, Fang Yang, Zhou Jiang, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 31, 2024
Ficonalkib (SY-3505) in Advanced ALK-Positive NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 1/2 StudyYuankai Shi, Xingsheng Hu, Xingya Li, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 10, 2025
Targeting Cystine Metabolism in the Lung Cancer Environment Enhances the Efficacy of Immune Checkpoint InhibitionYun Xu, Shumin Li, Jiaji Wu, et al.
The Lancet. Respiratory Medicine|June 13, 2024
Garsorasib in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trialZiming Li, Xiaomin Dang, Dingzhi Huang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 22, 2023
D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS<sup>G12C</sup> in Patients With NSCLC: Phase 1 Study ResultsZiming Li, Zhengbo Song, Yanqiu Zhao, et al.
Future Oncology (London, England)|June 3, 2026
Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 studyZhiwei Chen, Fang Yang, Zhou Jiang, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2025
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 studyZhengbo Song, Ziming Li, Yiping Zhang, et al.
Lancet (London, England)|May 31, 2026
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in ChinaShun Lu, Baogang Liu, Yongzhong Luo, et al.
Lancet (London, England)|October 22, 2025
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trialZhiwei Chen, Fang Yang, Zhou Jiang, et al.
Pageof 8